No Data
Zhejiang Garden Biopharmaceutical (300401.SZ): Zhejiang Garden Pharmaceutical obtained the pharmaceutical registration certificate for Alendronate Sodium Tablets.
Gelonghui, November 22nd丨 Zhejiang Garden Biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary Zhejiang Garden Pharmaceutical Co., Ltd. (hereinafter referred to as "Garden Pharmaceutical") recently received the "Drug Registration Certificate" for Alendronate Sodium Tablets approved and issued by the National Medical Products Administration. Alendronate Sodium Tablets are primarily used to treat osteoporosis in postmenopausal women and male osteoporosis to increase bone mass. Alendronate Sodium Tablets are classified as Type B in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)".
Express News | Zhejiang garden biopharmaceutical: Subsidiary obtained the registration certificate for alendronate sodium tablets pharmaceutical.
Zhejiang garden biopharmaceutical (300401.SZ): The company's convertible bonds vitamin A project has started production.
On November 11, Zhejiang Garden Biopharmaceutical (300401.SZ) stated on the investor interaction platform that the company's convertible bonds for the vitamin A project have already begun production.
Huafu Securities: BASF delays the resumption time of vitamins E and A production, prices are expected to continue to rise.
Due to the explosion, BASF delayed the resumption of production of vitamins E and A. After this news was announced, vitamins E and A quickly stopped falling and rebounded.
Zhejiang Garden Biopharmaceutical (300401.SZ): Vitamins B6 and biotin projects are actively progressing as planned.
On October 21, zhejiang garden biopharmaceutical (300401.SZ) stated on the investor interaction platform that the company's VA project now has production capacity, and vitamins B6 and biotin projects are actively progressing according to plan.
Zhejiang Garden Biopharmaceutical (300401.SZ): The production and sales of vitamin D3 in the third quarter increased year-on-year and quarter-on-quarter.
Gelonghui October 21st, zhejiang garden biopharmaceutical (300401.SZ) stated on the investor interaction platform that the production and sales of vitamin D3 in the third quarter of the company increased both year-on-year and quarter-on-quarter.
No Data
No Data